Agios Pharmaceuticals Secures Orphan Drug Designation for Tebapivat in Myelodysplastic Syndromes
Agios Pharmaceuticals secures FDA orphan-drug designation for its tebapivat treatment targeting rare blood cancers, specifically myelodysplastic syndromes (MDS). This...